Friday June 23rd 2017

Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α).

In this study, we found that DMF inhibited hypoxia- induced expression of HIF-1α and its target genes such as interleukin 8 (IL-8) and vascular endothelial growth factor (VEGF) in MC3T3 E1 cells. Mechanistically, DMF promoted HIF-1α degradation in a proteasome-dependent but von Hippel-Lindau (VHL) protein-independent manner. Importantly, we found that DMF disrupted the interaction between HIF-1α and its chaperone heat shock protein 90 (Hsp90) but promoted the interaction between HIF-1α and the receptor of activated protein kinase C (RACK1). These data suggest that DMF might promote degradation of HIF-1α by affecting its folding and maturation. Based on these observations, we conclude that DMF is a novel inhibitor of HIF-1α. PMID: 24569076 [PubMed – as supplied by publisher] (Sour…

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Link: 

Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α).

Leave a Comment

More from category

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]

MS Society Disappointed with Senate Healthcare Bill
MS Society Disappointed with Senate Healthcare Bill

/About-the-Society/News/HealthcareBill-6-22 [Read More]

Type I interferons could have role in natural improvement of RA during pregnancy
Type I interferons could have role in natural improvement of RA during pregnancy

An international US-Danish team of scientists, led by Damini Jawaheer, Ph.D. at the UCSF Benioff Children's Hospital [Read More]

Shared decision-making essential to optimal treatment and quality of life for patients with MS
Shared decision-making essential to optimal treatment and quality of life for patients with MS

One of the cornerstones of multiple sclerosis treatment is shared decision-making between patients and their doctors [Read More]

UC consortium formed to speed up development of new drugs
UC consortium formed to speed up development of new drugs

For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the [Read More]